Lisinopril ( DrugBank: Lisinopril )

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	1
46	悪性関節リウマチ	1
49	全身性エリテマトーデス	1
66	IgA腎症	2
67	多発性嚢胞腎	3
113	筋ジストロフィー	2
222	一次性ネフローゼ症候群	1

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-007482-21-GB (EUCTR)	09/11/2009	17/08/2009	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Fabry disease with proteinuria. MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria	Trade Name: perdix Product Name: perdix Trade Name: Zestoretic 10,20 Product Name: ZESTORIC Trade Name: INNOZIDE Product Name: innozide Trade Name: lisinopril Product Name: lisinopril Trade Name: zestril Product Name: zestril Trade Name: coversyl Product Name: coversyl Trade Name: coversyl PLUS Product Name: coversyl PLUS Trade Name: Accupro Product Name: Accupro Trade Name: Accuretic Product Name: Accuretic Trade Name: lopace Product Name: lopace Trade Name: lopace Product Name: lopace Trade Name: triapin Product Name: triapin& triapin Mite	Salford Royal NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes		Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-005295-32-GB (EUCTR)	01/02/2006	02/12/2005	Trial in rheumatoid arthritis of lisinopril (TRALIS) - TRALIS	Trial in rheumatoid arthritis of lisinopril (TRALIS) - TRALIS	Rheumatoid arthritis	Trade Name: Lisinopril Product Name: Lisinopril Product Code: N/A	Research and Development Department, Addenbrookes NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04486118 (ClinicalTrials.gov)	October 1, 2021	28/10/2019	Centrally Acting ACE Inhibition in SLE	A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE	Systemic Lupus Erythematosus	Drug: Lisinopril Pills;Drug: Benazepril Pill	Northwell Health	Lupus Research Alliance	Recruiting	18 Years	55 Years	All	36	Phase 2	United States

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-C000000006	2005/01/01	01/08/2005	Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety	Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety - Lisinopril only and a combination of lisinopril and losartan: A randomized controlled trial(JSKDC01)	IgA nephropathy in children	Lisinopril for 2 years Lisinopril+losartan for 2 years	Japanese Study group of Kidney Disease in Children	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	110	Not selected	Japan
2	JPRN-C000000373	1998/08/01	01/04/2006	Lisinopril for IgA nephropathy with focal mesangial proliferation in children	Lisinopril for IgA nephropathy with focal mesangial proliferation in children - Lisinopril for IgA nephropathy with focal mesangial proliferation in children	IgA nephropathy in children	Lisinopril for 2 years	The Japanese Pediatric IgA Nephropathy of Treatment Study Group	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	50	Not selected	Japan

67. 多発性嚢胞腎

臨床試験数 : 221 / 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01885559 (ClinicalTrials.gov)	January 2006	17/6/2013	HALT Progression of Polycystic Kidney Disease Study B	HALT Progression of Polycystic Kidney Disease Study B	Kidney, Polycystic	Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine	Completed	15 Years	64 Years	All	486	Phase 3	United States
2	NCT00283686 (ClinicalTrials.gov)	January 2006	26/1/2006	HALT Progression of Polycystic Kidney Disease Study A	HALT Progression of Polycystic Kidney Disease Study A	Kidney, Polycystic	Drug: Lisinopril;Drug: Telmisartan;Drug: Placebo;Other: Standard Blood Pressure Control;Other: Low Blood Pressure Control	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Boehringer Ingelheim;Merck Sharp & Dohme Corp.;Polycystic Kidney Disease Foundation;University of Pittsburgh;Washington University School of Medicine	Completed	15 Years	64 Years	All	558	Phase 3	United States
3	EUCTR2005-003182-16-GB (EUCTR)	26/08/2005	29/07/2005	Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.	Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.	Polycystic kidney disease	Trade Name: CARDURA Product Name: DOXAZOSIN Trade Name: MONOCOR Product Name: BISOPROLOL Trade Name: ZESTRIL Product Name: LISINOPRIL Trade Name: ISTIN Product Name: AMLODIPINE Trade Name: AMIAS Product Name: CANDESARTAN Trade Name: APRINOX Product Name: BENDROFLUMETHIAZIDE	Addenbrooke's Hospital Trust	NULL	Not Recruiting			Female: yes Male: yes	42	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01126697 (ClinicalTrials.gov)	February 2010	18/5/2010	Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies	PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies	Duchenne Muscular Dystrophy;Becker Muscular Dystrophy;Limb Girdle Muscular Dystrophy	Drug: Coenzyme Q10 and Lisinopril	Cooperative International Neuromuscular Research Group	United States Department of Defense	Completed	8 Years	N/A	All	63	Phase 2/Phase 3	United States;Canada;Japan
2	NCT01982695 (ClinicalTrials.gov)	March 2009	29/10/2013	Cardiomyopathy in DMD: Lisinopril vs. Losartan	Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy (DMD);Cardiomyopathy	Drug: Losartan;Drug: Lisinopril	Nationwide Children's Hospital	Boston Children’s Hospital;University of California, Davis;Unverisity of Kansas Medical Center;University of Minnesota - Clinical and Translational Science Institute;St. Louis Children's Hospital	Completed	N/A	N/A	Male	23	N/A	United States

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada

先頭へ